In a clinical trial involving patients with RAS or RAF mutant cancers, including KRAS mutant NSCLC, the combination showed a mPFS of 6.35 months with manageable toxicity, suggesting potential efficacy across different KRAS mutation variants [115]. This evidence concerns the gene KRAS and cancer.